US regulators have approved an Alzheimer’s drug from Biogen that split the scientific community, marking a significant moment for sufferers of the disease and their families. Ultimately the agency concluded that the overall benefits of aducanumab outweighed its risks for Alzheimer’s patients. The Alzheimer’s Association welcomed the decision, hailing it as a new day of hope for Alzheimer’s patients. “This approval is a victory for people living with Alzheimer’s and their families,” said Harry Johns, president of the Alzheimer’s Association. The FDA’s decision has ramifications for research into Alzheimer’s beyond Biogen.

Source: The Irish Times June 07, 2021 15:56 UTC